Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 20:14 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $181.00 | $271,500.00 |
DisclosureSEC source: 0001127602-20-024632 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,089 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 21:42 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $202.02 | $484,853.52 |
DisclosureSEC source: 0001127602-20-024651 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,402 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 18:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,132 | $177.55 | $200,986.60 |
DisclosureSEC source: 0001127602-20-023768 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 184,585 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 16:34 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $177.55 | $443,875.00 |
DisclosureSEC source: 0001127602-20-023863 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,275 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 22:37 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 5,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023726 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,982 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Effective August 14, 2020, executive is no longer subject to reporting. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:47 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023640 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:35 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 2,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023639 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:16 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 13,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023637 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,173 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:17 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 7,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023638 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,802 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:13 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 7,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023636 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,589 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,756 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,919 | $201.99 | $1,195,593.02 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,162 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $200.61 to $202.98. The price reported above reflects the weighted average sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Balance adjusted by duplicate reporting of 780 performance units earned on June 4, 2020 originally reported as banked shares on April 19, 2018. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:32 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $202.02 | $484,853.52 |
DisclosureSEC source: 0001127602-20-022720 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,474 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:13 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $200.06 | $300,090.00 |
DisclosureSEC source: 0001127602-20-022716 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,261 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2020 Filed Jul 18, 2020 01:26 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $196.98 | $492,450.00 |
DisclosureSEC source: 0001127602-20-021787 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,796 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 15:27 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,026 | $196.98 | $202,101.48 |
DisclosureSEC source: 0001127602-20-021696 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 185,717 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,675 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,919 | $194.64 | $1,152,090.14 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,942 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $192.70 to 197.30. The price reported above reflects the weighted average sale price. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 18:15 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $189.49 | $284,235.00 |
DisclosureSEC source: 0001127602-20-020804 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,761 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 15:14 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $189.63 | $455,111.52 |
DisclosureSEC source: 0001127602-20-021091 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,874 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 23:45 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,245 | $158.79 | $197,693.55 |
DisclosureSEC source: 0001127602-20-019805 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 186,743 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 23:43 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $158.79 | $396,975.00 |
DisclosureSEC source: 0001127602-20-019804 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,296 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:39 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 3,483 | $160.82 | $560,136.06 |
DisclosureSEC source: 0001127602-20-019135 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,942 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 6/1/2017. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:39 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 7,022 | $160.82 | $1,129,278.04 |
DisclosureSEC source: 0001127602-20-019135 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,425 F1 · kind: Represents performance-based restricted stock units granted on June 1, 2017. The shares were earned on June 4, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,594 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,919 | $160.61 | $950,660.06 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,403 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.05 to 162.18. The price reported above reflects the weighted average sale price. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 23:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $160.13 | $192,156.00 |
DisclosureSEC source: 0001127602-20-018533 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,274 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 108.59 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 01:37 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 239 | $161.12 | $38,507.68 |
DisclosureSEC source: 0001127602-20-018554 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,403 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 6/1/2017. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:22 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $160.13 | $240,195.00 |
DisclosureSEC source: 0001127602-20-018523 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,261 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 90.97 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 15, 2020 Filed May 19, 2020 14:17 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $162.05 | $405,125.00 |
DisclosureSEC source: 0001127602-20-017051 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,796 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 84.6316 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,228 | $162.05 | $198,997.40 |
DisclosureSEC source: 0001127602-20-017069 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 187,988 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,737 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 4,737 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,737 | $155.06 | $734,515.43 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,642 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $153.33 to 158.02. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 78.522 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,737 | $58.24 | $275,882.88 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:56 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $164.00 | $246,000.00 |
DisclosureSEC source: 0001127602-20-015378 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,670 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:44 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $164.00 | $196,800.00 |
DisclosureSEC source: 0001127602-20-015375 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,365 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 23:00 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $159.03 | $397,575.00 |
DisclosureSEC source: 0001127602-20-013947 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 23:13 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,222 | $159.03 | $194,334.66 |
DisclosureSEC source: 0001127602-20-013950 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 189,216 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,737 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,739 | $152.63 | $723,302.67 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $148.99 to 154.59. The price reported above reflects the weighted average sale price. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:25 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $150.00 | $180,000.00 |
DisclosureSEC source: 0001127602-20-013133 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,565 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 18:46 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $140.73 | $211,095.00 |
DisclosureSEC source: 0001127602-20-012994 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,170 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 21:18 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $137.49 | $343,725.00 |
DisclosureSEC source: 0001127602-20-011112 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 21:16 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,336 | $137.49 | $183,686.64 |
DisclosureSEC source: 0001127602-20-011109 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 190,438 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.